Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.21 USD
-0.01 (-0.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.23 +0.02 (1.65%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Galena Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -37.34 | -41.30 | -20.70 | -16.76 | -19.29 |
Depreciation/Amortization & Depletion | 0.00 | 10.00 | 1.13 | 0.28 | 2.83 |
Net Change from Assets/Liabilities | 3.35 | 6.11 | -8.56 | 5.59 | -1.11 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.59 | 1.38 | 2.11 | 0.47 | -0.07 |
Net Cash From Operating Activities | -31.41 | -23.81 | -26.02 | -10.42 | -17.64 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -5.50 | -4.50 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.50 | -4.50 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 22.35 | 24.08 | 12.07 | 38.13 | 19.57 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.03 | 0.00 | 0.00 | 0.31 | 0.00 |
Net Cash from Financing Activities | 22.32 | 24.08 | 12.07 | 38.44 | 19.57 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -14.60 | -4.23 | -13.95 | 28.03 | 1.93 |
Cash at Beginning of Period | 17.23 | 21.46 | 35.40 | 7.38 | 5.45 |
Cash at End of Period | 2.63 | 17.23 | 21.46 | 35.40 | 7.38 |
Diluted Net EPS | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 |
Fiscal Year End for Galena Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -17.04 | -9.57 | -37.34 | -29.20 | -19.94 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -4.49 | -1.81 | 3.35 | 0.66 | -1.05 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.09 | 0.61 | 2.59 | 1.96 | 1.30 |
Net Cash From Operating Activities | -20.44 | -10.76 | -31.41 | -26.59 | -19.69 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -5.50 | -5.50 | -2.50 |
Net Cash from Investing Activities | 0.00 | 0.00 | -5.50 | -5.50 | -2.50 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 27.06 | 26.65 | 22.35 | 18.93 | 18.88 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 |
Net Cash from Financing Activities | 27.06 | 26.65 | 22.32 | 18.93 | 18.88 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 6.62 | 15.89 | -14.60 | -13.16 | -3.32 |
Cash at Beginning of Period | 2.63 | 2.63 | 17.23 | 17.23 | 17.23 |
Cash at End of Period | 9.25 | 18.52 | 2.63 | 4.07 | 13.91 |
Diluted Net EPS | -0.13 | -0.21 | -0.23 | -0.33 | -0.31 |